H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data
H.C. Wainwright reiterated a Buy rating and $185 price target on Nektar Therapeutics (NKTR) after positive alopecia data. NKTR shares fell 22.4% on Oct 1, despite analysts' bullish consensus. NKTR reported a smaller-than-expected Q2 2026 loss but missed revenue expectations. NKTR won a $90M verdict against Eli Lilly.
How this was made
The 30-second read
Why it matters
The data release triggered a sharp share decline despite an analyst reaffirming a buy rating, indicating market skepticism about the durability of responses and the commercial potential of the alopecia program.
Market read
The mixed trial results and legal award create short‑term downside risk for NKTR, while the buy rating suggests some upside potential if later data improve.
What to watch
Potential future partnership opportunities for the alopecia asset and the company's cash runway through 2028.
Background
Nektar Therapeutics (NASDAQ: NKTR) is a clinical‑stage biotech focused on immuno‑oncology and dermatology. The REZOLVE‑AA Phase 2b trial data were presented at a major dermatology congress, and the company also reported a favorable court verdict against Eli Lilly.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $185 price target after Nektar Therapeutics presented Phase 2b alopecia trial data and disclosed a $90 million jury verdict against Eli Lilly.
likely continued pressure as investors digest mixed trial results and the sizable legal award
The trial data showed modest response durability and the stock already dropped sharply; no new positive catalyst was introduced.
Market effects
Biotech sector may see heightened scrutiny of early‑stage dermatology programs after mixed efficacy signals.
U.S. biotech stocks could face short‑term volatility in early‑trade as investors reassess trial pipelines.
Limited to investors tracking niche biotech and dermatology therapeutics worldwide.
Counterpoint
The $90 M legal win could offset trial concerns, offering a floor valuation for NKTR.
Key entities
- companyNektar Therapeutics
Biotech firm presenting Phase 2b alopecia data and receiving a $90 M jury award.
- analyst_firmH.C. Wainwright
Reiterated a Buy rating and $185 price target for NKTR.
- companyEli Lilly and Company
Defendant in the $90 M jury verdict case.
